Evidence map›Paper›PMID 21947198›Full record

ReviewEuropean journal of pediatrics2011

Eponym: Barth syndrome.

Atsuhito Takeda, Akira Sudo, Masafumi Yamada, Hirokuni Yamazawa, Gaku Izumi, Ichizo Nishino, Tadashi Ariga

Abstract readBiographyHistorical ArticlePortrait
PubMed Publisher
In one paragraph

Review in European journal of pediatrics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Barth Syndrome:Genes · 2025
    Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. New clinical and molecular insights on Barth syndrome.Orphanet journal of rare diseases · 2013
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Atsuhito TakedaDepartment of Pediatrics, Hokkaido University Graduate School of Medicine, North 15, West 7, Kita-ku, Sapporo 060-8638, Japan. a-takeda@med.hokudai.ac.jp
Akira Sudo
Masafumi Yamada
Hirokuni Yamazawa
Gaku Izumi
Ichizo Nishino
Tadashi Ariga
Hokkaido University · JPNational Center of Neurology and Psychiatry · JPSapporo City General Hospital · JPTokyo Women's Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledBarth syndrome (OMIM #302060) (BTHS) is an X-linked disorder of lipid metabolism characterized by skeletal myopathy, neutropenia, growth delay, and cardiomyopathy. It is caused by mutations in the tafazzin gene (TAZ), which lead to decreased production of an enzyme required to produce cardiolipin, a component of the inner mitochondrial membrane necessary for proper functioning of the electron transport chain. The most common initial presentation of BTHS is significant heart failure due to cardiomyopathy, which is the main cause of death in infancy or childhood. On the other hand, some patients have limited clinical features of BTHS. These patients may be overlooked or misdiagnosed with unclassified congenital myopathy, especially when heart failure is not clinically significant. However, these patients could also develop significant heart failure or life-threatening arrhythmias during or even after childhood. Heart failure in BTHS is often responsive to standard medical therapy, indicating early diagnosis is critical. Diagnostic clues of BTHS in the subclinical stage of heart failure include family histories, findings of lipid storage myopathy in the skeletal muscle biopsy, and elevated plasma brain natriuretic peptide levels. The genetic analysis of TAZ is the only confirmatory method for the diagnosis of BTHS.

conclusionphysicians should be aware of the possibility of this disease and carry out genetic studies when it is considered.

Indexed as

Barth SyndromeAcyltransferasesChildHeart FailureHistory, 21st CenturyHumansNetherlandsNeurologyPediatricsPrognosisTranscription FactorsAcyltransferasesTAFAZZIN protein, humanTranscription Factors

Identifiers

PMID21947198
OpenAlexW2077132217

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.